1STBIO Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $7.49M

  • Investors
  • 23

1STBIO General Information

Description

Developer of novel therapeutics designed to treat neurodegenerative, cancer, and rare diseases. The company develops drug candidates and a genomics-based discovery platform to identify therapeutic targets and biomarkers, enabling patients with conditions such as Parkinson's disease, cancer, and rare disorders to access potential treatments for unmet medical needs.

Contact Information

Website
www.1stbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • C-408, 338, Gwanggyojungang-ro
  • Suji-gu
  • Yongin, Gyeonggi-do 16942
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • C-408, 338, Gwanggyojungang-ro
  • Suji-gu
  • Yongin, Gyeonggi-do 16942
  • South Korea
+82

1STBIO Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

1STBIO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 03-Nov-2026 $7.49M Completed Clinical Trials - Phase 2
6. Secondary Transaction - Private 16-Jun-2026 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series D) 26-Jan-2026 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series C1) 01-Jul-2023 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 29-Jul-2020 Completed Clinical Trials - General
2. Early Stage VC (Series B) 17-Apr-2018 $17.7M $24.6M Completed Clinical Trials - General
1. Early Stage VC (Series A) 30-Nov-2016 $6.84M $6.84M Completed Clinical Trials - General
To view 1STBIO’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

1STBIO Patents

  • 89

    Total Documents Applications and Grants

  • Total Patents Families

  • 48

    Granted

  • 25

    Pending

  • Expiring in next 12 mo

1STBIO Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4499643-A1 Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same Pending 25-Mar-2022
EP-4499643-A4 Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same Pending 25-Mar-2022
US-20250197406-A1 Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same Pending 25-Mar-2022
WO-2023180976-A1 Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same Inactive 25-Mar-2022
JP-2025510271-A Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of use thereof Pending 25-Mar-2022 C07D487/04
To view 1STBIO’s complete patent history, request access »

1STBIO Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

1STBIO Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
Murex Partners Venture Capital Minority
SK Biopharmaceuticals Corporation Minority
AFW Partners Venture Capital Minority
ANDA Asset Management Hedge Fund Minority
CKD Venture Capital Corporate Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Ready to get started?

Request a free trial

1STBIO FAQs

  • When was 1STBIO founded?

    1STBIO was founded in 2016.

  • Where is 1STBIO headquartered?

    1STBIO is headquartered in Yongin, South Korea.

  • What is the size of 1STBIO?

    1STBIO has 40 total employees.

  • What industry is 1STBIO in?

    1STBIO’s primary industry is Drug Discovery.

  • Is 1STBIO a private or public company?

    1STBIO is a Private company.

  • What is 1STBIO’s current revenue?

    The current revenue for 1STBIO is .

  • How much funding has 1STBIO raised over time?

    1STBIO has raised $78.5M.

  • Who are 1STBIO’s investors?

    Murex Partners, SK Biopharmaceuticals, AFW Partners, ANDA Asset Management, and CKD Venture Capital are 5 of 23 investors who have invested in 1STBIO.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process